Nebi

Quick links to important sections

Nebi

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nebi

Quick Facts

Property Description
Active ingredient Nebivolol
Form Oral Tablet
Pharmacological class Beta-adrenergic antagonist
General purpose Management of high arterial pressure
Origin Synthetic compound

What Type of Medicine is Nebi? (Classification and Identity)

Nebi is a synthetic, prescription-only medicine whose active pharmaceutical ingredient is Nebivolol, which is classified as a beta-blocker. This medication is an oral preparation, commonly supplied as a tablet, and is clinically recognized as a third-generation beta-blocker.

The classification as a beta-adrenergic antagonist signifies its fundamental function: blocking the effects of adrenaline and other stress hormones on specific receptors within the heart and circulatory system. Nebivolol's status as a third-generation agent distinguishes it from earlier compounds, highlighting its selective action profile that preferentially targets receptors on the heart (beta-1).

Nebivolol: Composition and Unique Action Principle

The active compound Nebivolol is manufactured as a racemic mixture, consisting of two distinct stereoisomers, d-nebivolol and l-nebivolol, both necessary for the compound's overall therapeutic efficacy. The d-nebivolol delivers the core beta-blocking activity, while the l-nebivolol isomer contributes to the drug’s unique secondary action.

This composition enables a dual physiological effect: selective beta-1-receptor blockade coupled with vasodilation. This mechanism involves the promotion of nitric oxide (NO) release within the blood vessel walls. This action is key to its therapeutic profile, meaning the drug manages the heart's function while also helping arteries to relax and widen, easing blood flow.

General Purpose and Benefit of this Beta-Blocker Type

The overall function of this medication, driven by its simultaneous heart-rate-modulating and vasodilatory actions, is the sustained regulation and reduction of elevated arterial pressure. By decreasing the force of the heart's contraction and lowering peripheral vascular resistance, the medication reduces the total workload on the cardiovascular system. This compound is used for the management of chronic high arterial pressure in adult patients.

Regulatory References

  1. FDA classifies as a Beta-Blocker

What side effects are possible with Nebi?

Possible Side Effects and Safety Information for Nebi

The safety profile of Nebi is established through governmental regulatory documentation, identifying adverse reactions and conditions that require specific caution or limit its use. The most common adverse reactions documented in clinical trials include headache and fatigue.

Other commonly reported side effects include dizziness, slow heart rate (bradycardia), swelling (edema) in the hands or feet, and gastrointestinal effects such as diarrhea, constipation, and nausea.

Serious Adverse Reactions and Warnings

The following conditions have been associated with Nebi or the class of beta-blockers and represent significant safety concerns:

  • Abrupt Discontinuation: Stopping this medication suddenly, particularly in patients with pre-existing Coronary Artery Disease, carries a serious risk of exacerbation of angina, myocardial infarction (heart attack), and life-threatening irregular heart rhythms (ventricular arrhythmias). Tapering the dose slowly is required for discontinuation.
  • Bradycardia and Heart Block: Severe bradycardia and heart block greater than first degree are contraindications for its use due to the risk of serious cardiac complications.
  • Cardiogenic Shock and Decompensated Heart Failure: The medication is contraindicated in patients with cardiogenic shock, decompensated cardiac failure, and sick sinus syndrome (without a permanent pacemaker).

Population-Specific Safety Considerations

  • Hepatic Impairment: Nebi is contraindicated in patients with severe hepatic impairment. Caution and dosage adjustment are necessary for patients with moderate hepatic impairment.
  • Renal Impairment: Caution is advised in patients with severe renal impairment due to decreased drug clearance.
  • Diabetes and Thyrotoxicosis: The use of Nebi may mask the common clinical signs of hypoglycemia (low blood sugar), such as a rapid heart rate, in diabetic patients. Similarly, it may mask signs of hyperthyroidism (thyrotoxicosis); abrupt withdrawal in these patients could precipitate a thyroid storm.
  • Pediatric Use: Safety and effectiveness have not been established in the pediatric population.

Drug Interactions

Concomitant use of Nebi with strong inhibitors of the CYP2D6 enzyme can increase the concentration of the drug in the body, which may necessitate a reduction in dosage. Caution is also warranted when used with other drugs that slow the heart rate, such as verapamil- or diltiazem-type calcium channel blockers, to avoid excessive reductions in heart function.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Nebivolol is primarily characterized by the severe consequences of excessive beta-blockade, as documented in official regulatory labeling. Individuals may exhibit a cluster of symptoms indicative of cardiovascular and systemic depression.

Overdose Manifestations Severe/Emergency Outcomes
Cardiovascular: Slow heart rate (bradycardia), low blood pressure (hypotension), dizziness, or fainting. Critical Cardiovascular: Heart failure, heart block, or circulatory collapse.
Systemic/CNS: Confusion, shakiness, sweating, nervousness, irritability, or changes in behavior. Neurological/Respiratory: Seizure, trouble breathing (bronchospasm), or unconsciousness (coma).

When Immediate Medical Help is Required

Regulators mandate that emergency services (e.g., 911) must be contacted immediately if the individual experiences collapse, a seizure, severe breathing difficulty, or is unresponsive. For advice on overdose management, the official labeling directs individuals to call the Poison Control Helpline (1-800-222-1222).

Management procedures, which are symptomatic and supportive, may include administering beta-agonists (such as dobutamine or isoproterenol) to help reverse the beta-blocking effects. Hypoglycemia (low blood sugar) is noted as a specific concern in the pediatric population following this type of overdose. Hospital monitoring is necessary for vital signs and continuous cardiac function assessment.

Therapeutic Uses of Nebi

Nebi is generally relevant for the long-term management of chronic cardiovascular conditions, contributing to easing systemic strain. The core uses of the medicine include the following therapeutic domains.


Management of Chronic High Blood Pressure

This medication is commonly used to help with chronic hypertension (high blood pressure) in adult patients, applied in situations where symptoms related to systemic imbalance or persistently elevated pressure require supportive management. The key therapeutic benefit is the sustained reduction of high arterial pressure, which contributes to easing the overall symptom load on the heart and is considered relevant for supporting general well-being during symptomatic phases. This is further applied in situations involving cardiovascular overload driven by persistent pressure and symptoms related to heightened physiological activity.

Supportive Care for Stable Heart Failure

Nebi is also considered relevant as an adjunctive measure in the treatment of stable, mild to moderate chronic heart failure in older adult patients. This usage provides supportive relief by assisting in the management of symptoms linked to organ-specific functional stress. The benefit to patients is a more stable management of their chronic condition, which may assist with maintaining functional stability and supports patients during difficult episodes by easing distress.


Quick Fact: This medication is relevant for easing symptoms that create noticeable functional strain associated with persistent arterial pressure and chronic heart failure.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Nebi — Official Regulatory Information


Eligibility Scope

Classification Eligible Population Prohibited Population
Standard Use Adults with Hypertension Pediatric patients (Use not established)
Severe Condition Severe Bradycardia, Heart Block > 1^circ, Cardiogenic Shock
Organ Function Moderate Hepatic Impairment (Conditional) Severe Hepatic Impairment (Contraindicated)

Eligibility Classifications (High-Level)

Eligibility Severity Classification: Contraindicated, Not Recommended, Conditional Use (Requires Initial Restriction), Use Not Established.

Regulatory Basis: FDA Prescribing Information, EMA Summary of Product Characteristics.

Eligibility-Context Constraints: Cardiac Conduction, Organ Function (Hepatic/Renal), Age/Developmental Stage, Hypersensitivity.


Resulting Eligibility Structure

Official Eligibility Statements:

  • The medicine is contraindicated in patients with severe bradycardia and decompensated cardiac failure.
  • Safety and efficacy have not been established for pediatric use.
  • Severe renal impairment (CrCl < 30 mL/min) necessitates conditional use with an initial restriction.
  • Breastfeeding is not recommended due to Nebivolol being present in breast milk.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define strict criteria for use, primarily prohibiting the medicine in populations with underlying severe cardiac or circulatory instability and severe liver dysfunction. Use is not recommended for the pediatric population because its safety profile has not been established. Eligibility for use in certain patient groups, such as those with kidney or moderate liver impairment, is conditional and subject to specific official restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail several categories of drug interactions involving Nebivolol, structured around both metabolic processes and cardiovascular effects.

Pharmacokinetic Interactions

Mechanism Interacting Substances (Examples) Official Outcome
CYP2D6 Enzyme Inhibition Fluoxetine, Paroxetine, Quinidine, Propafenone Co-administration increases Nebivolol plasma levels (exposure/AUC) because the medicine is primarily metabolized by CYP2D6. A dose reduction may be required.

Pharmacodynamic Interactions

Substance Class Official Effect Regulatory Constraint
Calcium Channel Blockers (Verapamil, Diltiazem-type) May cause excessive reductions in heart rate (bradycardia), blood pressure, and cardiac contractility. Intravenous Verapamil with a beta-blocker is advised against.
Digitalis Glycosides Increased risk of bradycardia due to additive effects on atrioventricular conduction. Monitor closely for signs of low heart rate.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) May lead to a loss of antihypertensive effect and increased risk of renal impairment. Not formally contraindicated, but effect antagonism is documented.
Clonidine (Centrally-Acting) May produce excessive reduction of sympathetic activity. The regulatory label requires Nebivolol be discontinued days before Clonidine is gradually tapered.

Interactions with Food and Substances

Nebivolol and alcohol (ethanol) may have additive effects in lowering blood pressure. Furthermore, Multivitamins with Minerals may decrease Nebivolol's effects through inhibition of gastrointestinal absorption, necessitating a separation of administration times by at least 2 hours as stated in regulatory-aligned sources.

Mechanism of Action

The core mechanism involves the selective antagonism of beta1-adrenergic receptors, primarily by the D-Nebivolol component. By blocking the binding of stress hormones like norepinephrine, this action reduces catecholamine-mediated signaling of the Sympathetic Nervous System (SNS). This molecular event decreases intracellular cyclic AMP (cAMP) and subsequent calcium ion ( Ca^2+) influx into cardiac myocytes, leading to a reduction in heart rate and the force of contraction (negative chronotropy and inotropy). A distinct secondary mechanism involves the modulation of the vascular endothelium, largely influenced by the L-Nebivolol component. This targets beta3-receptors to activate the Endothelial Nitric Oxide Synthase (eNOS) system, leading to increased production of Nitric Oxide (NO). NO acts as a key mediator, causing arterial smooth muscle to relax, resulting in vasodilation and a subsequent reduction in Total Peripheral Resistance (TPR). The drug’s activity is defined by the synergistic action of its two enantiomers, ensuring both cardiac and vascular systems are modulated simultaneously. This combination results in the physiological modulation of cardiac output and peripheral resistance, influencing activity within multiple key pathways that govern systemic arterial pressure.

Dosage and Administration Information

How to Use Nebi: Administration Guidelines

Nebi (nebivolol) is an oral tablet taken once daily. Its usage is defined by the needs of the patient and the condition being managed, following established pharmaceutical protocols.


Administration and Dosage Regimens

The medication is to be taken once daily and may be administered with or without food. Nebivolol tablets are available in multiple strengths, including 2.5 mg, 5 mg, 10 mg, and 20 mg.

Condition Starting Dose Maximum Daily Dose
Hypertension (High Blood Pressure) 5 mg once daily 40 mg once daily
Chronic Heart Failure (CHF) (Elderly ≥ 70) 1.25 mg once daily 10 mg once daily

For hypertension, the dose may be increased at intervals of 2 weeks. For chronic heart failure, the initial dose is titrated (increased) slowly in steps (1.25 mg, 2.5 mg, 5 mg, and 10 mg) at 1–2 week intervals under specialized supervision.


Special Procedural Instructions

  • Organ Impairment: Patients with severe kidney or moderate liver impairment should initiate treatment with a lower starting dose of 2.5 mg once daily, followed by cautious titration.
  • Discontinuation: Therapy must not be stopped abruptly. If treatment must be discontinued, the instruction is to gradually reduce the dose over a period of 1 to 2 weeks to avoid acute physiological stress.
  • Pediatric Use: The safety and efficacy of Nebi have not been established in pediatric patients, and its use is not recommended in this population.

These instructions constitute the standardized approach to the medicine's administration.

Recent Clinical Evidence

Research Evidence for Managing Chronic High Blood Pressure

Research examining Nebivolol for high blood pressure was sourced primarily from short-term, randomized controlled trials (RCTs). These studies were designed to compare the measured outcomes in patients receiving the medicine against either a placebo (an inactive treatment) or other established medications. Researchers monitored outcomes related to physiological strain, mainly focusing on the change in Systolic and Diastolic Blood Pressure (SBP and DBP), which was the primary goal of the short-term trials. The observation periods were typically short, often 8 to 12 weeks.

Findings describe patterns of measured differences in blood pressure levels observed in patients receiving Nebivolol compared to those receiving placebo. Data from active-controlled trials also reported how outcomes changed in the observed populations relative to other agents.


Research Evidence for Supportive Care in Stable Heart Failure

Studies exploring Nebivolol in the context of stable heart failure, a condition marked by functional limitations, was primarily established by one large, long-term randomized controlled trial. This research examined the medicine in conjunction with other standard treatments. The core study monitored the time it took for patients to experience serious events, such as the composite endpoint of all-cause mortality or cardiovascular hospitalization.

When researchers examined the all-cause mortality outcome alone, the measured difference was not statistically significant. The evidence contributes to the broader evidence landscape for beta-blockers in heart failure, but the reliance on a single primary trial and its results are reflected in the varying regulatory authorizations and guidelines across geographical regions for this condition.


Long-Term Studies and Durability of Effect

For the hypertension indication, research exploring long-term effects on major cardiovascular events is not fully established. Most evidence focuses on short-term symptom changes over periods of 8 to 12 weeks, and the durability of the response over many years is not well characterized. In contrast, the main heart failure trial was designed as a long-term study, with patients observed for a mean duration of nearly two years, gathering crucial long-term data on event-based outcomes for that specific study period.


Evidence in Specific Patient Populations

Nebivolol was evaluated in several specific patient groups to see how findings may differ.

  • Older Adults: The largest dedicated long-term research was studied for use in a population limited to older adults (aged 70 years and older). This means the results apply only to the populations studied, and the long-term event data does not automatically extend to younger adults with the same condition.
  • African American/Black Patients: Separate trials were conducted specifically to examine Nebivolol's effects on blood pressure in African American/Black patients with hypertension. These studies reported patterns observed in this group that sometimes differed from those seen in non-Black patient populations.

Frequently Asked Questions (FAQ)

Common questions about Nebi (FAQ)


Q: Is Nebi the same type of medicine as other blood pressure pills?

A: Nebi is classified as a beta-adrenergic blocking agent, or beta-blocker, by official sources. This type of medicine works to regulate the heart and blood vessels differently than other common blood pressure medicines like ACE inhibitors or diuretics. Official documents note that Nebi may be used alone or in combination with other blood pressure agents.


Q: How quickly does Nebi start working after I take the first pill?

A: Regulatory guidance suggests that the effects of a specific dose are typically monitored and assessed over a period of weeks. The maximum recommended dose adjustment interval is usually two weeks for high blood pressure, indicating that the full stabilizing effect of a change is not immediate and is generally monitored gradually by a healthcare provider.


Q: How long do the effects of Nebi last after taking a dose?

A: Official administration guidelines state that Nebi is intended to be taken once daily. This once-daily dosing indicates that the medicine is formulated and expected to maintain its effect in the body over a 24-hour period.


Q: What happens if I take too much Nebi by mistake?

A: Official documentation describes that taking too much of the medicine (an overdose) may cause symptoms such as a slowed heart rate (bradycardia), very low blood pressure (hypotension), or potentially difficulty breathing. Official regulatory documents indicate that emergency medical attention is required.


Q: Does Nebi interact with supplements like herbal remedies?

A: Official patient information sheets generally caution that all current medicines, including vitamins and herbal products, should be discussed with a health professional for review. This allows a health professional to review the complete profile of substances being taken.


Q: Is Nebi suitable for people with diabetes?

A: Nebi can be used by patients with diabetes, according to official warnings. However, the medicine may mask the common signs of low blood sugar (hypoglycemia), such as a rapid heartbeat. Regulatory warnings indicate that close monitoring of blood sugar levels may be necessary.


Q: Can Nebi be taken on an empty stomach?

A: The official product information specifies that Nebi may be taken with or without food.


Q: Do I have to keep taking Nebi even if my blood pressure improves?

A: Official regulatory warnings strongly advise against stopping the medicine suddenly, as this may be associated with a risk of worsening the underlying condition. The need for continued treatment is part of an ongoing management plan determined by a health professional.


Q: Is Nebi generally safe for older people?

A: The supportive use of Nebi for heart failure was specifically studied in older adults (aged 70 years and older), according to clinical trial summaries in official documents. This indicates that this population group was included in the research and is a primary demographic for the heart failure indication.


Q: What happens if I miss a dose of Nebi?

A: Regulatory-aligned patient instructions typically describe the procedure if a dose is missed: taking it as soon as remembered unless it is near the next scheduled time. The instruction is to never take two doses at once to make up for a missed dose.


Q: Are there any foods or drinks I need to avoid when taking Nebi?

A: The official label does not require avoiding specific foods, as it can be taken with or without food. However, official sources note that alcohol may increase the effect of lowering blood pressure, which is a consideration for a health professional.


Q: Can I take pain relievers like ibuprofen while using Nebi?

A: Official drug interaction lists include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen. The combination requires discussion with a health professional, as the official effect noted is a potential loss of the medicine's blood pressure-lowering effect.


Q: Does Nebi cause weight gain?

A: While not listed among the most frequent adverse reactions, official regulatory records include unusual weight gain or loss as a less common or post-marketing report associated with the medicine's use.


Q: Is it common to feel tired when starting Nebi?

A: Official documentation lists fatigue (tiredness) as one of the most common adverse reactions reported during initial clinical trials. This suggests that feeling tired can be expected by many people when beginning treatment with this medicine.


Q: Can Nebi affect my sleep?

A: Official regulatory lists of side effects include insomnia (difficulty sleeping) and nightmares as uncommon adverse reactions. These effects are not reported to occur frequently.


Q: Can Nebi cause problems with sexual function?

A: Official regulatory documents list erectile dysfunction as an uncommon adverse reaction associated with the use of the medicine.


Q: Is Nebi used for conditions other than high blood pressure?

A: In addition to high blood pressure (hypertension), the medicine is officially authorized and indicated for the supportive treatment of stable chronic heart failure in specific patient populations, such as those aged 70 years and older.


Q: What should I do if I feel dizzy after taking Nebi?

A: Dizziness is a common side effect listed in official documents. General regulatory-aligned patient advice often describes sitting or lying down if dizziness occurs. It also describes rising slowly from a sitting or lying position to help prevent further dizziness or injury.


Q: Is there a generic version of Nebi available?

A: Yes, the active ingredient, nebivolol, is available as a generic medicine. Multiple manufacturers produce the generic product in the same strengths as the original, as recorded in official databases.


Q: Why do some people need to take Nebi twice a day?

A: Official dosing instructions state that the recommended administration is once daily. Regulatory documents explicitly note that a more frequent dosing regimen is unlikely to be beneficial for this medicine.


Q: Is Nebi generally safe for women of childbearing age?

A: Official regulatory documents caution that Nebi should not be used during pregnancy unless clearly necessary. Additionally, breastfeeding is not recommended because the medicine is known to pass into breast milk.


Q: Does Nebi affect mood or cause depression?

A: Official regulatory lists of side effects include depression as an uncommon adverse reaction associated with the use of the medicine.


Q: Are there any skin reactions linked to Nebi use?

A: Official regulatory lists of side effects include rash and itching (pruritus) as uncommon adverse reactions. Very rare reports also describe the aggravation of psoriasis.


Q: How is Nebi different from ACE inhibitors?

A: Nebi is classified as a beta-blocker, which primarily works by blocking the effects of stress hormones on the heart and blood vessels. ACE inhibitors are a separate class of medicine that primarily affects the body's hormone system to promote blood vessel relaxation. Both types are officially indicated for lowering high blood pressure.


Q: Is Nebi commonly prescribed as a first-line treatment?

A: The regulatory documents indicate Nebi is for the treatment of hypertension and may be used alone or in combination with other agents. Whether a medicine is prescribed first is generally determined by clinical practice guidelines and a patient's health profile, rather than by the regulatory label alone.


Q: Does Nebi cause dry mouth?

A: Official regulatory lists of side effects include dry mouth as a reported symptom. This is not listed among the most common adverse reactions, suggesting it is a less frequent occurrence.


Q: Can Nebi cause swelling in the legs or ankles?

A: Yes, official documentation lists edema (swelling) in the hands or feet as a common adverse reaction reported during initial clinical trials. This is a common effect observed during the use of this medicine.


Q: Is Nebi a common cause of cough?

A: Official regulatory lists of side effects include coughing as a common adverse reaction reported in clinical trials.


Q: What documents describe the main purpose of Nebi?

A: The main purpose of the medicine is described in core government documents such as the FDA Prescribing Information (under the Indications and Usage section) and the EMA Summary of Product Characteristics (under the Therapeutic Indications section).

How should Nebi be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific storage and handling conditions for Nebi (nebivolol) tablets.

Storage Conditions

Nebi must be stored at controlled room temperature, maintained between 20 C and 25 C (68 F and 77 F). The product must be protected from excessive heat, moisture, and direct light, and it must not be frozen. To maintain its integrity and for safety, the medicine should be kept in a closed container and must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Nebi must be disposed of in accordance with local regulations. It is not listed as a medicine suitable for flushing down a toilet or sink. The recommended procedure is to utilize a drug take-back program or, if unavailable, to mix the product with an undesirable substance (such as used coffee grounds or cat litter) and place the mixture in a sealed container for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nebi found in:

A-Z Index: